Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc (NVAX) is a clinical-stage biotechnology company pioneering vaccine development through recombinant nanoparticle technology and its proprietary Matrix-M adjuvant. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, clinical trial progress, and regulatory milestones.
Our curated collection of Novavax news ensures access to official press releases, financial disclosures, and strategic partnership announcements. Users will find updates spanning vaccine candidate advancements, manufacturing expansions, and peer-reviewed research findings. Key content areas include quarterly earnings reports, FDA regulatory submissions, and global health collaborations.
Bookmark this page for streamlined tracking of Novavax's progress in addressing infectious diseases like COVID-19, influenza, and RSV. The resource is regularly updated to serve as your primary source for verified information about NVAX's scientific innovations and market positioning.
Novavax (NASDAQ: NVAX) has announced its participation in the upcoming BofA Securities 2025 Health Care Conference in Las Vegas, Nevada. The company will engage in a fireside chat on Wednesday, May 14, 2025, from 3:00 to 3:30 PM PT. Additionally, Novavax will conduct investor meetings during the conference. The fireside chat will be accessible via webcast on the company's investor relations website at ir.novavax.com, with a replay available for 30 days following the event.
Novavax (NASDAQ: NVAX) has announced improved terms for its collaboration and license agreement with Takeda for Nuvaxovid®, their protein-based COVID-19 vaccine, in Japan. The amended agreement includes enhanced financial terms such as an upfront payment, payment for the 2024/2025 season, and annual milestone payments tied to regulatory approvals. Additionally, Novavax will receive royalties on net sales for each season moving forward.
The agreement ensures continued availability of Nuvaxovid®, a non-mRNA COVID-19 vaccine, in Japan - the world's third-largest pharmaceutical market. According to CEO John C. Jacobs, this strengthened partnership validates Novavax's technology platform and Matrix-M® adjuvant while positioning the company as a partner of choice.
Novavax (NASDAQ: NVAX) has scheduled its first quarter 2025 financial results and operational highlights conference call for May 8, 2025, at 8:30 a.m. Eastern Time. Participants can join through phone registration or direct dial-in, with connection recommended 10 minutes before the start time.
A replay of the conference call will be available from 11:30 a.m. ET on May 8 until 11:59 p.m. ET on May 15, 2025. The webcast replay will remain accessible through June 7, 2025, on the company's investor relations website.
Novavax has appointed Charles Newton as an independent director to its Board of Directors. Newton, currently serving as Chief Financial Officer of Lyell Immunopharma, brings extensive experience in healthcare investment banking and public markets to the role.
Newton's background includes leadership positions at major financial institutions including Bank of America Merrill Lynch, Credit Suisse, and Morgan Stanley. He currently serves on the boards of Coherus BioSciences and 2seventy bio. Newton holds a BS in Finance from Miami University and an MBA from The Tuck School at Dartmouth College.
The appointment aligns with Novavax's corporate growth strategy, which focuses on developing strategic partnerships for their R&D assets and Matrix-M® adjuvant technology platform. CEO John C. Jacobs emphasized that Newton's expertise in corporate finance and capital markets will be valuable for the company's future direction.
Novavax (NVAX) has announced preliminary results from the SHIELD-Utah study comparing its COVID-19 Vaccine (2024-2025 Formula) targeting the JN.1 strain with Pfizer-BioNTech's mRNA vaccine. The real-world study, conducted between September-December 2024, demonstrated significantly lower reactogenicity in Novavax recipients.
Key findings show Novavax recipients experienced an average of 1.7 symptoms versus 2.8 in Pfizer-BioNTech recipients. Only 24.2% of Novavax recipients reported Grade 2 or higher symptoms compared to 43.8% for Pfizer-BioNTech. Local reactogenicity events were 12.5% lower in Novavax recipients.
The study, conducted at University of Utah Health with 219 Novavax and 369 Pfizer-BioNTech recipients, also revealed reduced impact on daily activities. Novavax recipients reported fewer hours of missed work (0.7 vs 1.4h) and less productivity impact (0.8 vs 2.4h) compared to Pfizer-BioNTech recipients.
Novavax (NVAX) announced significant changes to its Board of Directors. James Young, PhD, who served as Chair since 2011, is retiring effective March 10, 2025. Margaret McGlynn, RPh, a board member since 2020, has been appointed as the new Chair. Additionally, John Shiver, PhD, joins as an independent director.
During Young's 15-year tenure, Novavax achieved several milestones, including the acquisition of Isconova and Matrix-M™ adjuvant, global approvals and commercialization of its first COVID-19 vaccine, and partnership with Sanofi in 2024. The company is pursuing a new corporate growth strategy focused on strategic partnerships for R&D assets and Matrix-M™ adjuvant.
McGlynn brings experience as former President of Merck Vaccines and Infectious Disease and CEO of International AIDS Vaccine Initiative. Dr. Shiver contributes over 30 years of vaccine, biologics, and RNA therapeutics expertise, having led teams developing vaccine candidates for over 40 diseases.
Novavax (Nasdaq: NVAX) has announced its management team's upcoming participation in investor conferences scheduled for March. The company will provide access to webcasts of the fireside chat and presentation through their investor relations website at ir.novavax.com. These recordings will remain available for replay for a 30-day period following the conferences.
Novavax (NVAX) reported its Q4 and full year 2024 financial results, highlighting significant strategic shifts and financial performance. The company achieved total revenue of $88 million in Q4 and $682 million for full year 2024, down from $291 million and $984 million respectively in 2023.
Key developments include transitioning Nuvaxovid™ COVID-19 vaccine commercial responsibility to Sanofi for the 2025-2026 season, completing a $200 million sale of its Czech Republic facility to Novo Nordisk (saving $80 million annually), and securing a $50 million milestone payment under the Sanofi agreement. The company ended 2024 with over $1 billion in cash and receivables.
For 2025, Novavax expects Adjusted Licensing, Royalties and Other Revenue between $300-350 million, including potential milestone payments of $225 million for US BLA approval and market authorizations.
Novavax (NVAX) has announced it will host a conference call on Thursday, February 27, 2025, at 8:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results and operational highlights. The company, which specializes in protein-based vaccines with its Matrix-M™ adjuvant technology, will provide participants with options to join the call either through automated registration or operator assistance.
FAQ
What is the current stock price of Novavax (NVAX)?
What is the market cap of Novavax (NVAX)?
